J
Jason E. Gestwicki
Researcher at University of California, San Francisco
Publications - 280
Citations - 27231
Jason E. Gestwicki is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Chaperone (protein) & Heat shock protein. The author has an hindex of 69, co-authored 250 publications receiving 23446 citations. Previous affiliations of Jason E. Gestwicki include Research Triangle Park & Stanford University.
Papers
More filters
Journal ArticleDOI
Luminescence complementation assay for measurement of binding to protein C-termini in live cells.
TL;DR: It is found that HEK293 cells that stably express these chimeras under a doxycycline promoter produced a robust luminescence signal, and it is anticipated that NanoBiT is well-suited for studying PPIs that involve C-termini.
Posted ContentDOI
Caspase inhibition mitigates tau cleavage and neurotoxicity in iPSC-induced neurons with the V337M MAPT mutation
Panos Theofilas,Chao Wang,David Butler,Dulce Ovando Morales,Cathrine Petersen,Brian Chin,Teddy Yang,Shireen Khan,Raymond T. Ng,Rakez Kayed,Celeste M. Karch,Bruce L. Miller,Jason E. Gestwicki,Li Gan,Li Gan,Sally Temple,Michelle R. Arkin,Lea T. Grinberg +17 more
TL;DR: In this paper, the authors proposed a model in which time-dependent accumulation of caspase-cleaved tau in V337M MAPT neurons promotes neurotoxicity that is reversed by caspases-6 inhibition.
Patent
Inhibitors of alpha-crystallin aggregation for the treatment for cataract
TL;DR: In this article, the authors proposed a method to detect and prevent cataracts in a subject having or at risk of developing Cataracts by using cc-crystallin aggregation inhibitors.
Posted ContentDOI
The small molecule KHS101 induces bioenergetic dysfunction in glioblastoma cells through inhibition of mitochondrial HSPD1
Euan S. Polson,Verena Kuchler,Christopher Abbosh,Edith M. Ross,Ryan K. Mathew,Hester A. Beard,Eulashini Chuntharpursat-Bon,Jennifer Williams,Barbara da Silva,Hao Shao,Anjana Patel,Adam J. Davies,Alastair Droop,Hollie B. S. Griffiths,Paul Chumas,Susan C Short,Mihaela Lorger,Jason E. Gestwicki,Lee D. Roberts,Robin S. Bon,Simon J. Allison,Shoutian Zhu,Florian Markowetz,Heiko Wurdak +23 more
TL;DR: Targeting of HSPD1-dependent oncometabolic pathways as an anti-GBM therapy is suggested to reduce intracranial GBM xenograft tumor growth upon systemic administration, without discernible side effects.
Journal ArticleDOI
N-myc mediated translation control is a therapeutic vulnerability in medulloblastoma.
Duygu Kuzuoğlu-Öztürk,Ozlem Aksoy,Christin Schmidt,Robin Lea,Jon D. Larson,Ryan R L Phelps,Nicole Nasholm,Megan Holt,Adrian Contreras,Miller Huang,Shannon Toy Wong-Michalak,Hao Shao,Robert J. Wechsler-Reya,T. J. Phillips,Jason E. Gestwicki,Davide Ruggero,William A. Weiss +16 more
TL;DR: The data unexpectedly revealed that N-myc regulates the expression of specific components of the protein folding machinery at the translational level through the major cap binding protein, eukaryotic initiation factor eIF4E, which suppressed tumor growth in mouse and human medulloblastoma xenograft models.